When stored properly at 2-8 degrees Celsius, they retain potency until the printed date, which is typically 18-24 months from manufacture
Wegovy got FDA approval in 2021 specifically for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related health condition
Notably, testing in animals also showed that it worked without some of the drugs side effects such as nausea, constipation and significant loss of muscle mass
Wegovy is an under-the-skin, self-administered injectable prescription medicine for patients with either: A body mass index (BMI) of 30 kg/m2 or greater A BMI of 27 kg/m2 or greater with at least one weight-related ailment such as type 2 diabetes, hypertension, sleep apnea, or others
FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes
The efficacy of semaglutide as a weight loss treatment option has been demonstrated in several clinical trials, including the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) and PIONEER (Peptide Innovation for Early Diabetes Treatment) trials for type 2 diabetes, as well as the STEP (Semaglutide Treatment Effect in People with Obesity) trials, which specifically focused on weight loss
